TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26515269

Group type: EXPERIMENTAL
Intervention: Oral melatonin (0.5 mg/kg)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Oral midazolam (0.5 mg/kg)
Number of subjects: 92
Study: 24486687

Group type: EXPERIMENTAL
Intervention: Combination of 0.2% Glyceryl Trinitrate and 2% lignocaine ointment (Group A)
Number of subjects: 192

Group type: COMPARATOR
Intervention: 2% lignocaine ointment (Group B)
Number of subjects: 192

Group type: COMPARATOR
Intervention: 0.2% Glyceryl Trinitrate ointment (Group C)
Number of subjects: 192
Study: 21769664

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months
Number of subjects: 7868

Group type: EXPERIMENTAL
Intervention: Incident clinical fractures
Number of subjects: 7868

Group type: EXPERIMENTAL
Intervention: Incident clinical vertebral fractures
Number of subjects: 7868

Group type: EXPERIMENTAL
Intervention: Assessment <3 months post fracture
Number of subjects: 7868
Study: 19393880

Group type: EXPERIMENTAL
Intervention: Aspheric IOL group
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Spherical IOL group
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study: 17244902

Group type: EXPERIMENTAL
Intervention: Eccentric loading
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Repetitive low-energy shock-wave therapy (SWT)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Wait and see
Number of subjects: 75
Study: 15978302

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol 250/50 microg BID (FSC)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Ipratropium/albuterol 36/206 microg QID (IB/ALB)
Number of subjects: 361
Study: 12785670

Group type: EXPERIMENTAL
Intervention: Energy conservation course
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control period of traditional treatment
Number of subjects: 37
Study: 10234599

Group type: EXPERIMENTAL
Intervention: Ganciclovir 1000 mg q8h with zalcitabine 0.75 mg q8h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ganciclovir 1000 mg q8h with stavudine 40 mg q12h
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ganciclovir 1000 mg q8h alone
Number of subjects: 0
Study: 8598547

Group type: EXPERIMENTAL
Intervention: 15 mg vitamin A (retinyl palmitate)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Vitamin A supplemented infants with normal RDR
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Vitamin A supplemented infants with abnormal RDR
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Vitamin A supplemented infants
Number of subjects: 165
Study: 1959720

Group type: EXPERIMENTAL
Intervention: Inhaled fenoterol, 0.2 mg 4 times daily for 7 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 7034771

Group type: EXPERIMENTAL
Intervention: Peripheral iridectomy with thermal sclerostomy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 15
Study: 31801245

Group type: EXPERIMENTAL
Intervention: GnRHa
Number of subjects: 111

Group type: COMPARATOR
Intervention: Cyclophosphamide
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide plus GnRHa
Number of subjects: 111
Study: 28544279

Group type: EXPERIMENTAL
Intervention: Brief scripted education and advice on percentage probability of falling in the next 6 months; intervention group size: 63 patients.
Number of subjects: 412

Group type: COMPARATOR
Intervention: Control group; size: 67 patients.
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Intervention group (brief education).
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Intervention group (brief education) for patients presenting with a fall.
Number of subjects: 412

Group type: COMPARATOR
Intervention: Control group.
Number of subjects: 412
Study: 25010996

Group type: EXPERIMENTAL
Intervention: barefoot
Number of subjects: 35

Group type: COMPARATOR
Intervention: uncushioned minimalist shoes
Number of subjects: 35

Group type: COMPARATOR
Intervention: cushioned ultraflexible shoes
Number of subjects: 35

Group type: COMPARATOR
Intervention: standard running shoes
Number of subjects: 35
Study: 23375357

Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (VIB)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Classical balance training (BAL)
Number of subjects: 57
Study: 21911534

Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery
Number of subjects: 115

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Change in alignment
Number of subjects: 115
Study: 19281636

Group type: EXPERIMENTAL
Intervention: Two doses of 40 mg/kg praziquantel with 2 weeks interval
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single dose of 40 mg/kg praziquantel
Number of subjects: 0
Study: 16718542

Group type: EXPERIMENTAL
Intervention: Strong African American Families Program (SAAF)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 172
Study: 12761264

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no PTA)
Number of subjects: 62
Study: 10636605

Group type: EXPERIMENTAL
Intervention: Psychosocially enhanced treatment program (PET)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Case management-oriented outpatient treatment program (CM)
Number of subjects: 84
Study: 9077497

Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6) detection in brain tissue using double-label immunohistochemistry technique
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: IL-6 association with astrocytes
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Comparison of IL-6 and HLA-DR expression
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Role of IL-6 in inflammatory demyelinating disorders
Number of subjects: 6
Study: 8417772

Group type: EXPERIMENTAL
Intervention: Parental presence during dental treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Parental absence during dental treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Parental presence (viewing from behind a one-way mirror)
Number of subjects: 32
Study: 3804028

Group type: EXPERIMENTAL
Intervention: Cimetidine plus sulpiride 200 mg daily
Number of subjects: 73

Group type: COMPARATOR
Intervention: Cimetidine 800 mg daily
Number of subjects: 73
Study: 29356277

Group type: COMPARATOR
Intervention: New complex cream composed of Yunnan Portulaca oleracea extract, Prinsepia utilis oil, beta‐glucan, and sodium hyaluronate, applied twice daily for 28 days.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control cream (tolerance‐extreme cream), applied twice daily for 28 days.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: New complex cream
Number of subjects: 20
Study: 29231520

Group type: EXPERIMENTAL
Intervention: Quick needle insertion therapy at Aqiang point
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine acupuncture at Lianquan (CV 23)
Number of subjects: 80
Study: 24758164

Group type: EXPERIMENTAL
Intervention: Individualised audit and feedback (A&F) strategies for antibiotic prescribing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current audit practice
Number of subjects: 0
Study: 21766336

Group type: EXPERIMENTAL
Intervention: Stepped Care Program (SCP)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Care As Usual (CAU)
Number of subjects: 136
Study: 20189926

Group type: EXPERIMENTAL
Intervention: Light intensity exercise
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (age-matched women without a cancer diagnosis)
Number of subjects: 50
Study: 18673366

Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 315
Study: 17058829

Group type: EXPERIMENTAL
Intervention: Acupuncture therapy (DFIPRS) in addition to anti-asthmatic medicine
Number of subjects: 71

Group type: COMPARATOR
Intervention: Anti-asthmatic medicine only (control group)
Number of subjects: 71
Study: 14516215

Group type: EXPERIMENTAL
Intervention: Warning about misleading information
Number of subjects: 0

Group type: COMPARATOR
Intervention: Misleading postevent information
Number of subjects: 0
Study: 10834678

Group type: EXPERIMENTAL
Intervention: Dopamine at a renal dose (2.5 microg/kg/min)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Epinephrine infusion
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Dopamine at higher doses (10 microg/kg/min)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Neither epinephrine nor dopamine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Presence of renal failure
Number of subjects: 19
Study: 8800254

Group type: EXPERIMENTAL
Intervention: Veterinarians enrolled in a dairy production medicine continuing education program (treatment herds)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Veterinarians not enrolled in the program (control herds)
Number of subjects: 153
Study: 1364078

Group type: EXPERIMENTAL
Intervention: Clozapine (500 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorpromazine (600 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neuroleptics
Number of subjects: 0
Study: 6370976

Group type: EXPERIMENTAL
Intervention: Nomifensine (150 mg/day)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 156
Study: 29133604

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 10142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10142
Study: 26820423

Group type: EXPERIMENTAL
Intervention: Mortality salience (MS)
Number of subjects: 293
Study: 25022939

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patches (maximum maintenance dose of 16 mg/24 h)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patches
Number of subjects: 174
Study: 22465317

Group type: COMPARATOR
Intervention: Pravastatin (placebo-controlled trial)
Number of subjects: 2078

Group type: EXPERIMENTAL
Intervention: Non-HDL cholesterol
Number of subjects: 2078

Group type: EXPERIMENTAL
Intervention: LDL cholesterol
Number of subjects: 2078

Group type: EXPERIMENTAL
Intervention: HDL cholesterol
Number of subjects: 2078

Group type: EXPERIMENTAL
Intervention: Highest natural quartile of non-HDL cholesterol
Number of subjects: 2078
Study: 20009770

Group type: EXPERIMENTAL
Intervention: SPIRO 50 mg once daily for 12 weeks
Number of subjects: 111

Group type: COMPARATOR
Intervention: BFZ 2.5 mg once daily for 12 weeks
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: SPIRO 50 mg
Number of subjects: 111

Group type: COMPARATOR
Intervention: BFZ 2.5 mg
Number of subjects: 111
Study: 18500597

Group type: EXPERIMENTAL
Intervention: Glycogel dressing
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard wound dressing care
Number of subjects: 100
Study: 15926441

Group type: EXPERIMENTAL
Intervention: Computerized injection device
Number of subjects: 64

Group type: COMPARATOR
Intervention: Traditional syringe
Number of subjects: 64
Study: 12422152

Group type: EXPERIMENTAL
Intervention: Point-of-care BNP assay
Number of subjects: 1050
Study: 10351924

Group type: EXPERIMENTAL
Intervention: Zafirlukast (20 mg twice a day)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (200 microg twice a day)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 7496001

Group type: EXPERIMENTAL
Intervention: Triple combination of 50 mg isoniazid + 120 mg rifampicin + 300 mg pyrazinamide
Number of subjects: 250

Group type: COMPARATOR
Intervention: Separate administration of the 3 antituberculosis drugs
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Both groups (triple combination and separate drugs)
Number of subjects: 250
Study: 1766329

Group type: EXPERIMENTAL
Intervention: Pedagogic format
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-fidelity format
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Problem-solving format
Number of subjects: 0
Study: 7006544

Group type: EXPERIMENTAL
Intervention: 1 mL/kg of 50% dextrose in water (D50W)
Number of subjects: 36

Group type: COMPARATOR
Intervention: 5% dextrose in water (D5W)
Number of subjects: 36
Study: 31726963

Group type: EXPERIMENTAL
Intervention: Clopidogrel-Aspirin therapy
Number of subjects: 2933
Study: 31266924

Group type: EXPERIMENTAL
Intervention: Mobile navigation program
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study: 29047413

Group type: EXPERIMENTAL
Intervention: VHA-guided transfusion therapy
Number of subjects: 392

Group type: COMPARATOR
Intervention: CCT-guided transfusion therapy
Number of subjects: 392

Group type: COMPARATOR
Intervention: CCT-guided therapy
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: VHA-guided therapy
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Surviving patients
Number of subjects: 392
Study: 25994664

Group type: EXPERIMENTAL
Intervention: Ulipristal acetate (UPA)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 23679679

Group type: EXPERIMENTAL
Intervention: Nicotine (2 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Smokers (nicotine satiation)
Number of subjects: 60
Study: 21646441

Group type: EXPERIMENTAL
Intervention: Pregabalin add-on therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 20024757

Group type: EXPERIMENTAL
Intervention: HIV-related stigma (measured by Internalized Shame and Perceived Stigma)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Emotional social support
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Internalized shame and emotional social support
Number of subjects: 408
Study: 17536120

Group type: EXPERIMENTAL
Intervention: EGCG (300 mg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: EGCG (150 mg twice daily for two weeks)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: EGCG (acute treatment)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: EGCG (two weeks treatment)
Number of subjects: 42
Study: 15467101

Group type: EXPERIMENTAL
Intervention: Chromium picolinate (Cr-pic) supplementation (924 ug Cr/d)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Resistive training (RT)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: High dose Cr-pic
Number of subjects: 32
Study: 11426898

Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg and 50 mg
Number of subjects: 53
Study: 11120458

Group type: EXPERIMENTAL
Intervention: Intensive diabetes management (IDM)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Enalapril (0.25 mg/kg/day)
Number of subjects: 17
Study: 9105164

Group type: EXPERIMENTAL
Intervention: C II treatment (chicken cartilage soup containing heat degenerated C II)
Number of subjects: 38
Study: 8456751

Group type: EXPERIMENTAL
Intervention: Initial mean minimal diameter of 74 coronary obstructions was 1.94 ± 0.09 mm; follow-up showed a reduction of 0.12 ± 0.04 mm (6%) in minimal diameter (p < 0.005).
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Initial mean 'normal' reference diameter was 3.06 ± 0.11 mm.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Using a minimal change of 0.27 mm in arterial diameter as a categoric variable.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Initial severity of disease as a determinant of progression.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Age as a factor in disease progression.
Number of subjects: 26
Study: 2951824

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide, 40 micrograms + fenoterol, 400 micrograms
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide, 0.5 mg + fenoterol, 2.0 mg
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 31608144

Group type: EXPERIMENTAL
Intervention: Composite pain patterns from L5 and S1 nerve roots
Number of subjects: 93

Group type: COMPARATOR
Intervention: Composite pain patterns shown to clinicians
Number of subjects: 93

Group type: COMPARATOR
Intervention: Use of composite pain drawings
Number of subjects: 93
Study: 29869044

Group type: EXPERIMENTAL
Intervention: Sparse representation-based variable selection (SRVS) for patient-specific genetic marker selection
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: SRVS method
Number of subjects: 851
Study: 27018896

Group type: EXPERIMENTAL
Intervention: Local administration of depomedrol
Number of subjects: 50

Group type: COMPARATOR
Intervention: BMP-2 with saline (control)
Number of subjects: 50
Study: 25535146

Group type: EXPERIMENTAL
Intervention: α‐lipoic acid
Number of subjects: 90

Group type: COMPARATOR
Intervention: Vitamin C
Number of subjects: 90
Study: 22459779

Group type: EXPERIMENTAL
Intervention: Unilateral valve placement aiming for total occlusion of one lobe
Number of subjects: 22

Group type: COMPARATOR
Intervention: Bilateral valve placement in two contralateral lobes with incomplete closure
Number of subjects: 22
Study: 20201624

Group type: EXPERIMENTAL
Intervention: Internet-based coaching, daily use of proprietary olfactive-based personal care products, and periodic feedback reports (Group 1)
Number of subjects: 562

Group type: COMPARATOR
Intervention: Online coaching only (Group 2)
Number of subjects: 562

Group type: COMPARATOR
Intervention: No active stress management program (Group 3)
Number of subjects: 562
Study: 18398227

Group type: EXPERIMENTAL
Intervention: FISH device
Number of subjects: 297

Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 297
Study: 15812451

Group type: EXPERIMENTAL
Intervention: ECM plus unprotected powder enzymes
Number of subjects: 14

Group type: COMPARATOR
Intervention: ECM alone
Number of subjects: 14
Study: 12200654

Group type: EXPERIMENTAL
Intervention: Quantitative ultrasound (QUS) indices
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: Cutoff levels of QUS indices for osteoporosis diagnosis
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: QUS indices
Number of subjects: 659
Study: 10080400

Group type: EXPERIMENTAL
Intervention: Polyclonal antibody ATG for DGF
Number of subjects: 83

Group type: COMPARATOR
Intervention: Conventional immunosuppression (CI) for IGF
Number of subjects: 83
Study: 8530600

Group type: EXPERIMENTAL
Intervention: Sublingual testosterone cyclodextrin (SLT; 2.5 mg, administered three times per day)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Sublingual testosterone cyclodextrin (SLT; 5.0 mg, administered three times per day)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Testosterone enanthate (TE; 200 mg, given once every 20 days by IM injections)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: All groups (including SLT and TE)
Number of subjects: 63
Study: 2009248

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 840
Study: 31540791

Group type: EXPERIMENTAL
Intervention: Conventionally fractionated or moderately hypofractionated radiotherapy (78 Gy in 39 fractions over 7.8 weeks or 62 Gy in 20 fractions over 4 weeks)
Number of subjects: 874

Group type: COMPARATOR
Intervention: Stereotactic body radiotherapy (36.25 Gy in five fractions over 1-2 weeks)
Number of subjects: 874
Study: 28806532

Group type: EXPERIMENTAL
Intervention: Oral phosphate load (PHOS; liquid supplement containing 1200 mg of phosphorus)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Oral phosphate load (PHOS)
Number of subjects: 17
Study: 26475373

Group type: EXPERIMENTAL
Intervention: Interactive face-to-face informational program alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interactive face-to-face informational program followed by an Internet-based booster
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 0
Study: 24494282

Group type: EXPERIMENTAL
Intervention: Acupuncture therapy at specific points (Yaoyangguan, Mingmen, Zhiyang, Shenzhu, Dazhui, Yamen, Fengfu, Baihui, Neck‐Jiaji) given 6 times a week for 21 days.
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Acupuncture group clinical efficacy 96.77% (30/31), adverse reactions 6.45% (2/31).
Number of subjects: 70

Group type: COMPARATOR
Intervention: Not applicable (control group).
Number of subjects: 70
Study: 21717781

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (Ashi‐point, Baihui (GV 20), Taiyang (EX‐HN 5), Shuaigu (GB 8), Fengchi (GB 20), Benshen (GB 13), Lieque (LU 7), needles retained for 30 min, once daily, 6 times a week for 4 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medication treatment (Flunarizine 10 mg, once every night for 4 weeks)
Number of subjects: 60
Study: 19735405

Group type: EXPERIMENTAL
Intervention: Pentax AirwayScope
Number of subjects: 140

Group type: COMPARATOR
Intervention: Glidescope
Number of subjects: 140
Study: 18261355

Group type: EXPERIMENTAL
Intervention: Anticoagulant treatment
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Thrombolytic treatment
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (healthy persons)
Number of subjects: 37
Study: 15207952

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 15245

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 15245
Study: 11810777

Group type: EXPERIMENTAL
Intervention: Endocrine therapy (oral tamoxifen for five years; premenopausal patients received bilateral ovary ablation followed by tamoxifen for five years)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Chemotherapy (CTX + MTX + 5‐Fu + VCR + DXM (CMFVP) or CTX + MTX + 5‐Fu (CMF))
Number of subjects: 369
Study: 9569476

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine combined with diphtheria and tetanus toxoids (PRP-T)
Number of subjects: 262
Study: 8049029

Group type: EXPERIMENTAL
Intervention: Sperm collection in serum medium (SM)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sperm collection in sterile cup (DRY)
Number of subjects: 16
Study: 2567739

Group type: EXPERIMENTAL
Intervention: Oral administration of 12 mg acrivastine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Colonic administration of 12 mg acrivastine
Number of subjects: 6